Use

Epidermal Growth Factor Receptor (EGFR) overexpression occurs in a variety of tumor types—including breast, prostate, ovarian, brain, lung, and predominantly squamous cell carcinomas—and is often associated with poor prognosis and shorter disease‑free survival. In colon carcinomas, EGFR expression is seen in more than 1% of invasive tumor cells. Patients whose tumors express EGFR and are wild‑type for KRAS mutation may be eligible for cetuximab therapy. Note: EGFR immunohistochemistry using clone D38B1 is not mutation‑specific and does not predict response to EGFR tyrosine kinase inhibitors in lung adenocarcinoma; mutation analysis by PCR or NGS is the appropriate test for that indication.